Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
GTG1 Therapeutics, Inc. logo

G1 Therapeutics, Inc. (GTHX)

NASDAQ Global Select · Currency in USD
$7.16 ▲ +0.01 (+0.14%)
At close: Sep 17, 3:56 PM ET. Market closed.
$7.14 ▼ -0.02 (-0.28%)
After hours: Sep 17, 7:44 PM ET

Summary

Previous Close
$7.15
Open
$7.15
Day's Range
$7.14 – $7.16
52 Week Range
$1.08 – $7.19
Volume
1,097,310
Avg. Volume
2,177,041
Market Cap
$377.75M
Beta (5Y Monthly)
1.68
PE Ratio (TTM)
--
EPS (TTM)
-$0.93
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.50

Profile: G1 Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
100
CEO
John E. Bailey Jr.

G1 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical enterprise focused on identifying, advancing, and ultimately commercializing small-molecule therapeutics to address various cancers. Their flagship commercial offering, COSELA, is designed to reduce chemotherapy-induced bone marrow suppression in adult patients with extensive-stage small cell lung cancer, administered prior to specific platinum/etoposide- or topotecan-containing regimens. The company is also actively progressing several investigational compounds.

Earnings

DateEst.Actual
Aug 8, 2024-$0.17-$0.10Beat
May 1, 2024-$0.19-$0.20Miss
Feb 28, 2024-$0.27-$0.21Beat
Nov 1, 2023-$0.31-$0.35Miss
Aug 2, 2023-$0.22$0.14Beat
May 3, 2023-$0.64-$0.53Beat

Analyst view

Consensus price target
$4.50 ▼ -37.2%
Range $3.00 – $6.00
Rating: Buy
Buy 82% · Hold 9% · Sell 9%

Get free alerts on GTHX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.